Letters sent to healthcare professionals in July 2017

Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.

In July 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

Article citation: Drug Safety Update volume 11 issue 1, August 2017: 4.

Published 15 August 2017